2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quinoxaline (NBQX) increases fibroblast growth factor mRNA levels after contusive spinal cord injury.
We have previously demonstrated that the glutamatergic receptor (AMPA) antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quinoxaline (NBQX) reduces functional deficits in a standardized rat model of contusive spinal cord injury (SCI). NBQX not only acted to protect neurons from excitotoxicity but also, unexpectedly, enhanced sparing of white matter including axons of descending pathways. We have therefore investigated mechanisms through which NBQX could produce beneficial effects for white matter. We report here that NBQX elicits a rapid and selective induction of FGF2 mRNA levels in injured spinal cord. This novel effect could contribute to the therapeutic properties of NBQX in the treatment of SCI.
Follesa
P
P
Department of Cell Biology, Georgetown University, School of Medicine, Washington, DC 20007, USA.
Wrathall
J R
JR
Mocchetti
I
I
D000818:Animals; D003288:Contusions / Q000378:metabolism*; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D005346:Fibroblast Growth Factors / Q000235:genetics*; D007796:Laminectomy; D011810:Quinoxalines / Q000494:pharmacology*; D012333:RNA, Messenger / Q000378:metabolism*; D051381:Rats; D013119:Spinal Cord Injuries / Q000378:metabolism*; D014018:Tissue Distribution
D018691:Excitatory Amino Acid Antagonists; D011810:Quinoxalines; D012333:RNA, Messenger; C062865:2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline; D005346:Fibroblast Growth Factors